Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68


Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.

Burgess EF, Livasy C, Hartman A, Robinson MM, Symanowski J, Naso C, Doherty S, Guerrieri R, Riggs S, Grigg CM, Clark PE, Raghavan D.

Urol Oncol. 2019 Jan 16. pii: S1078-1439(19)30002-X. doi: 10.1016/j.urolonc.2019.01.002. [Epub ahead of print]


Rate of radial scars by core biopsy and upgrading to malignancy or high-risk lesions before and after introduction of digital breast tomosynthesis.

Phantana-Angkool A, Forster MR, Warren YE, Livasy CA, Sobel AH, Beasley LM, Trufan SJ, Hadzikadic-Gusic L, Sarantou T, Voci AE, Sarma D, White RL Jr.

Breast Cancer Res Treat. 2018 Sep 21. doi: 10.1007/s10549-018-4973-x. [Epub ahead of print] Review.


Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.

Norris EJ, Jones WD, Surleac MD, Petrescu AJ, Destephanis D, Zhang Q, Hamadeh I, Kneisl JS, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol Rep. 2018 Jan 17;23:41-44. doi: 10.1016/j.gore.2018.01.005. eCollection 2018 Feb.


Breast cancer metastatic to the liver with hepatoid features and hepatocyte paraffin 1 positivity mimicking hepatocellular carcinoma.

Affleck A, Lyman WB, Jacobs C, Livasy CA, Martinie JB, Iannitti DA, Vrochides D.

Histopathology. 2018 Sep;73(3):529-531. doi: 10.1111/his.13644. Epub 2018 Jun 22. No abstract available.


Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.

Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, Mardis ER, Parker JS, Chen M, Anders CK, Carey LA, Perou CM.

J Clin Invest. 2018 Apr 2;128(4):1371-1383. doi: 10.1172/JCI96153. Epub 2018 Feb 26.


HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.


A tumor specific antibody to aid breast cancer screening in women with dense breast tissue.

Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P.

Genes Cancer. 2017 Mar;8(3-4):536-549. doi: 10.18632/genesandcancer.134.


Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY.

Breast Cancer Res Treat. 2017 Aug;165(1):181-191. doi: 10.1007/s10549-017-4303-8. Epub 2017 Jun 2.


Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.

Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS; I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ.

Breast Cancer Res. 2015 May 29;17:73. doi: 10.1186/s13058-015-0582-3.


Breast cancer detection in axillary sentinel lymph nodes: the impact of the method of pathologic examination.

Calhoun BC, Chambers K, Flippo-Morton T, Livasy CA, Armstrong EJ 3rd, Symanowski JT, Sarantou T, Greene FL, White RL Jr.

Hum Pathol. 2014 Dec;45(12):2497-501. doi: 10.1016/j.humpath.2014.09.004. Epub 2014 Oct 2.


Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies.

Calhoun BC, Sobel A, White RL, Gromet M, Flippo T, Sarantou T, Livasy CA.

Mod Pathol. 2015 May;28(5):670-6. doi: 10.1038/modpathol.2014.159. Epub 2014 Nov 21.


Mitigating overdiagnosis and overtreatment in breast cancer: what is the role of the pathologist?

Calhoun BC, Livasy CA.

Arch Pathol Lab Med. 2014 Nov;138(11):1428-31. doi: 10.5858/arpa.2013-0763-ED. Epub 2014 Mar 14. Review. No abstract available.


Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer.

Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB.

Int J Oncol. 2014 Feb;44(2):563-72. doi: 10.3892/ijo.2013.2197. Epub 2013 Nov 29.


αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, Shusta EV, Anders CK, Cryns VL.

Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.


Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.

Roll JD, Rivenbark AG, Sandhu R, Parker JS, Jones WD, Carey LA, Livasy CA, Coleman WB.

Exp Mol Pathol. 2013 Dec;95(3):276-87. doi: 10.1016/j.yexmp.2013.09.001. Epub 2013 Sep 14.


Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

Kimple RJ, Horton JK, Livasy CA, Shields JM, Lawrence JA, Chiu WM, Ivanova A, Ollila DW, Carey LA, Halle JS, Sartor CI, Dees EC.

Oncologist. 2012;17(12):1496-503. doi: 10.1634/theoncologist.2012-0256. Epub 2012 Sep 24.


Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8.


Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.


Endodermal sinus tumor of the ovary in an 86 year old woman.

Lange S, Livasy C, Tait DL.

Gynecol Oncol Case Rep. 2012 Feb 27;2(2):65-6. doi: 10.1016/j.gynor.2012.02.003. eCollection 2012.


Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.


Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK.

Breast Cancer Res. 2011;13(6):R125. doi: 10.1186/bcr3071. Epub 2011 Dec 1.


The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.

Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA.

Cancer. 2011 Apr 15;117(8):1602-11. doi: 10.1002/cncr.25746. Epub 2010 Nov 29.


Local control following single-dose intraoperative radiotherapy prior to surgical excision of early-stage breast cancer.

Kimple RJ, Klauber-DeMore N, Kuzmiak CM, Pavic D, Lian J, Livasy CA, Chiu WM, Moore DT, Sartor CI, Ollila DW.

Ann Surg Oncol. 2011 Apr;18(4):939-45. doi: 10.1245/s10434-010-1392-6.


Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.

Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.


Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):575-81. doi: 10.1016/j.ijrobp.2009.12.063.


Cosmetic outcomes for accelerated partial breast irradiation before surgical excision of early-stage breast cancer using single-dose intraoperative radiotherapy.

Kimple RJ, Klauber-DeMore N, Kuzmiak CM, Pavic D, Lian J, Livasy CA, Esler L, Moore DT, Sartor CI, Ollila DW.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):400-7. doi: 10.1016/j.ijrobp.2009.10.032. Epub 2010 Apr 13.


Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution review.

Milam MR, Abaid L, dos Reis R, Frumovitz M, Gehrig PA, Livasy C, Broaddus RR, Ramirez PT.

Ann Surg Oncol. 2010 Apr;17(4):1106-10. doi: 10.1245/s10434-009-0870-1. Epub 2009 Dec 29.


Effect of breast compression on lesion characteristic visibility with diffraction-enhanced imaging.

Faulconer LS, Parham CA, Connor DM, Kuzmiak C, Koomen M, Lee Y, Cho KR, Rafoth J, Livasy CA, Kim E, Zeng D, Cole E, Zhong Z, Pisano ED.

Acad Radiol. 2010 Apr;17(4):433-40. doi: 10.1016/j.acra.2009.10.020. Epub 2009 Dec 29.


Radiologist evaluation of an X-ray tube-based diffraction-enhanced imaging prototype using full-thickness breast specimens.

Faulconer L, Parham C, Connor DM, Zhong Z, Kim E, Zeng D, Livasy C, Cole E, Kuzmiak C, Koomen M, Pavic D, Pisano E.

Acad Radiol. 2009 Nov;16(11):1329-37. doi: 10.1016/j.acra.2009.05.006. Epub 2009 Jul 10.


FAK overexpression and p53 mutations are highly correlated in human breast cancer.

Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG.

Int J Cancer. 2009 Oct 1;125(7):1735-8. doi: 10.1002/ijc.24486.


Triple-Negative Breast Carcinoma.

Livasy CA.

Surg Pathol Clin. 2009 Jun;2(2):247-61. doi: 10.1016/j.path.2009.02.005. Epub 2009 Jun 2. Review.


Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway.

Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, Livasy C, Ketelsen D, Nepal DB, Perou CM, Patterson C, Klauber-Demore N.

Cancer Res. 2009 Jun 1;69(11):4621-8. doi: 10.1158/0008-5472.CAN-08-3402. Epub 2009 May 19.


A compact VEGF signature associated with distant metastases and poor outcomes.

Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM.

BMC Med. 2009 Mar 16;7:9. doi: 10.1186/1741-7015-7-9.


Use of the ThinPrep method in bile duct brushings: analysis of morphologic parameters associated with malignancy and determination of interobserver reliability.

Waugh MS, Guy CD, Maygarden SJ, Livasy CA, Jones CK, Volmar KE.

Diagn Cytopathol. 2008 Sep;36(9):651-6. doi: 10.1002/dc.20855.


Histological characteristics of singleton placentas delivered before the 28th week of gestation.

Hecht JL, Allred EN, Kliman HJ, Zambrano E, Doss BJ, Husain A, Pflueger SM, Chang CH, Livasy CA, Roberts D, Bhan I, Ross DW, Senagore PK, Leviton A; Elgan Study Investigators.

Pathology. 2008 Jun;40(4):372-6. doi: 10.1080/00313020802035865.


Molecular characterization of human breast tumor vascular cells.

Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, Reynolds E, Tanner C, Moore DT, Gabrielli F, Perou CM, Klauber-DeMore N.

Am J Pathol. 2008 May;172(5):1381-90. doi: 10.2353/ajpath.2008.070988. Epub 2008 Apr 10.


Characterization of chorioamnionitis in 2nd-trimester C-section placentas and correlation with microorganism recovery from subamniotic tissues.

Hecht JL, Onderdonk A, Delaney M, Allred EN, Kliman HJ, Zambrano E, Pflueger SM, Livasy CA, Bhan I, Leviton A; ELGAN Study Investigators.

Pediatr Dev Pathol. 2008 Jan-Feb;11(1):15-22. doi: 10.2350/07-06-0285.1.


Epidemiology of basal-like breast cancer.

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM.

Breast Cancer Res Treat. 2008 May;109(1):123-39. Epub 2007 Jun 20. Erratum in: Breast Cancer Res Treat. 2008 May;109(1):141. Dressler, Lynn G [added].


Reference weights for placentas delivered before the 28th week of gestation.

Hecht JL, Kliman HJ, Allred EN, Pflueger SM, Chang CH, Doss BJ, Roberts D, Livasy CA, Bhan I, Zambrano E, Ross DW, Senagore P, Husain AN, Leviton A.

Placenta. 2007 Oct;28(10):987-90. Epub 2007 Jun 18.


Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.

Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB.

Exp Mol Pathol. 2007 Oct;83(2):188-97. Epub 2007 Apr 18.


Identification of a basal-like subtype of breast ductal carcinoma in situ.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.

Hum Pathol. 2007 Feb;38(2):197-204.


Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively.

Ollila DW, Klauber-DeMore N, Tesche LJ, Kuzmiak CM, Pavic D, Goyal LK, Lian J, Chang S, Livasy CA, Sherron RF, Sartor CI.

Ann Surg Oncol. 2007 Feb;14(2):660-9.


Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.


Axillary lymph node count is lower after neoadjuvant chemotherapy.

Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N.

Am J Surg. 2006 Jun;191(6):827-9.


The molecular portraits of breast tumors are conserved across microarray platforms.

Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM.

BMC Genomics. 2006 Apr 27;7:96.


Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic.

Klauber-DeMore N, Ollila DW, Moore DT, Livasy C, Calvo BF, Kim HJ, Dees EC, Sartor CI, Sawyer LR, Graham M 2nd, Carey LA.

Ann Surg Oncol. 2006 May;13(5):685-91. Epub 2006 Mar 9.


Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.


The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.

Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC.

Breast Cancer Res. 2005;7(6):R871-80. Epub 2005 Sep 6.


Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.

Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van't Veer LJ.

Cancer Res. 2005 Oct 15;65(20):9155-8.


EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.

Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA.

Gynecol Oncol. 2006 Jan;100(1):101-6. Epub 2005 Sep 12.


Supplemental Content

Loading ...
Support Center